
TANDEM DIABETES CARE INC
TNDMNASDAQTrading Snapshot
- Day Range
- $118.19 β $119.82
- 52-Week Range
- $10.25 β $29.65
- Volume
- $2.57B
- Avg Volume
- $3.36B
- Shares Outstanding
- 68.5M
- Next Earnings
- Sep 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $1.01B
- Last Q Revenue
- $255M
- P/E Ratio
- -25.2
- P/S Ratio
- 1.5x
- EPS (TTM)
- $-0.93
- Dividend Yield
- 0.00%
Why Investors Own TNDM
- βHigh-growth profile β revenue up +33.1% YoY with expanding US Equity exposure.
- βHealthy economics β 72% gross margin and 27% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About TANDEM DIABETES CARE INC
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
Otter Score Breakdown
βAnalyst Price Target
βLatest News & Updates
TANDEM DIABETES CARE INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift TNDM price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
TANDEM DIABETES CARE INC announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.